Published in Antimicrob Agents Chemother on June 01, 2003
Bench-to-bedside review: Appropriate antibiotic therapy in severe sepsis and septic shock--does the dose matter? Crit Care (2009) 1.11
Penetration of amphotericin B lipid formulations into pleural effusion. Antimicrob Agents Chemother (2007) 0.93
[Diagnosis and therapy of sepsis]. Clin Res Cardiol (2006) 0.87
Daptomycin: a novel lipopeptide antibiotic against Gram-positive pathogens. Infect Drug Resist (2010) 0.84
Continuous infusion of antibiotics in the critically ill: The new holy grail for beta-lactams and vancomycin? Ann Intensive Care (2012) 0.82
Pulmonary versus systemic delivery of antibiotics: comparison of vancomycin dispositions in the isolated rat lung. Antimicrob Agents Chemother (2007) 0.78
Periodontitis-associated septic pulmonary embolism caused by Actinomyces species identified by anaerobic culture of bronchoalveolar lavage fluid: a case report. BMC Infect Dis (2015) 0.75
A specially tailored vancomycin continuous infusion regimen for renally impaired critically ill patients. SAGE Open Med (2013) 0.75
Comparison of Continuous and Intermittent IV Infusion of Vancomycin: Systematic Review. Can J Hosp Pharm (2010) 0.75
Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother (1997) 17.36
Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med (1999) 10.21
The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med (1999) 7.64
Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother (2001) 1.87
Penetration of vancomycin into human lung tissue. J Antimicrob Chemother (1996) 1.52
Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections. Antimicrob Agents Chemother (1996) 1.29
Emergence of vancomycin-intermediate Staphylococcus aureus in a Belgian hospital: microbiological and clinical features. J Antimicrob Chemother (2002) 1.13
Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit. Antimicrob Agents Chemother (2000) 1.02
[Ventricular staphylococcal infections. Treatment with vancomycin by continuous venous infusion]. Presse Med (1986) 0.99
[Continuous infusion of vancomycin in post-neurosurgical staphylococcal meningitis in adults]. Presse Med (1993) 0.96
Comparison of bactericidal activities of intermittent and continuous infusion dosing of vancomycin against methicillin-resistant Staphylococcus aureus and Enterococcus faecalis. Pharmacotherapy (1998) 0.93
Continuous infusion of vancomycin in methicillin-resistant staphylococcus infection. Chemotherapy (1998) 0.87
A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis (2006) 4.29
Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet (2007) 3.11
Antibiotic strategies in severe nosocomial sepsis: why do we not de-escalate more often? Crit Care Med (2012) 2.39
Associations between cytomegalovirus infection and functional impairment and frailty in the BELFRAIL Cohort. J Am Geriatr Soc (2011) 2.38
A randomized clinical trial to compare fleroxacin-rifampicin with flucloxacillin or vancomycin for the treatment of staphylococcal infection. Clin Infect Dis (2004) 2.22
Preclinical evidence that sildenafil and vardenafil activate chloride transport in cystic fibrosis. Am J Respir Crit Care Med (2007) 2.18
Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care (2010) 2.11
The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics (2004) 2.06
A randomized placebo-controlled trial of miglustat in cystic fibrosis based on nasal potential difference. J Cyst Fibros (2012) 2.05
Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy. Crit Care (2011) 1.91
Disseminated Scedosporium apiospermum infection in a cystic fibrosis patient after double-lung transplantation. J Heart Lung Transplant (2006) 1.90
Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. Am J Respir Crit Care Med (2010) 1.71
Optimising vancomycin doses in continuous infusion for septic patients. Int J Antimicrob Agents (2011) 1.70
The European Register of Specialists in Clinical Chemistry and Laboratory Medicine: guide to the Register, version 3-2010. Clin Chem Lab Med (2010) 1.68
Mutations of the cystic fibrosis gene and intermediate sweat chloride levels in children. Am J Respir Crit Care Med (2002) 1.68
Effect of selective decontamination on antibiotic resistance. Lancet Infect Dis (2011) 1.60
β-lactam antibiotic concentrations during continuous renal replacement therapy. Crit Care (2014) 1.59
The impact of the assay for measuring albumin on corrected ('adjusted') calcium concentrations. Nephrol Dial Transplant (2009) 1.43
Prolonged unconsciousness in a patient on automated peritoneal dialysis. Eur J Emerg Med (2006) 1.38
Asymmetrical action of the canine diaphragm after single-lung inflation. J Appl Physiol (1985) (2011) 1.38
Hemolytic uremic syndrome in Belgium: incidence and association with verocytotoxin-producing Escherichia coli infection. Clin Microbiol Infect (1999) 1.33
Congenital tracheal malformation in cystic fibrosis transmembrane conductance regulator-deficient mice. J Physiol (2008) 1.30
Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenomics (2011) 1.27
Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Crit Care (2010) 1.26
Imaging infection with 18F-FDG-labeled leukocyte PET/CT: initial experience in 21 patients. J Nucl Med (2006) 1.24
Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. Transplantation (2005) 1.21
Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens. Antimicrob Agents Chemother (2011) 1.21
SUMOylation of tissue transglutaminase as link between oxidative stress and inflammation. J Immunol (2009) 1.14
Azithromycin reduces spontaneous and induced inflammation in DeltaF508 cystic fibrosis mice. Respir Res (2006) 1.12
Potentiation of cyclophosphamide chemotherapy using the anti-angiogenic drug thalidomide: importance of optimal scheduling to exploit the 'normalization' window of the tumor vasculature. Cancer Lett (2006) 1.11
Azithromycin reduces exaggerated cytokine production by M1 alveolar macrophages in cystic fibrosis. Am J Respir Cell Mol Biol (2009) 1.11
Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban. Thromb Haemost (2013) 1.02
Cystic fibrosis is associated with a defect in apical receptor-mediated endocytosis in mouse and human kidney. J Am Soc Nephrol (2007) 1.02
The BELFRAIL (BFC80+) study: a population-based prospective cohort study of the very elderly in Belgium. BMC Geriatr (2010) 1.01
Basic protocol for transepithelial nasal potential difference measurements. J Cyst Fibros (2004) 1.01
Validation of an ELISA-based screening assay for the detection of amphetamine, MDMA and MDA in blood and oral fluid. Forensic Sci Int (2005) 1.01
Cystic fibrosis: insight into CFTR pathophysiology and pharmacotherapy. Clin Biochem (2012) 1.01
The EC4 European syllabus for post-graduate training in clinical chemistry and laboratory medicine: version 4--2012. Clin Chem Lab Med (2012) 0.99
Indolent Pasteurella multocida peritonitis in a CCPD patient. 25 years of "cat-bite peritonitis": a review. Perit Dial Int (2005) 0.99
Gene expression in human thyrocytes and autonomous adenomas reveals suppression of negative feedbacks in tumorigenesis. Proc Natl Acad Sci U S A (2005) 0.98
In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy. Int J Antimicrob Agents (2010) 0.96
Determinants of early inadequate vancomycin concentrations during continuous infusion in septic patients. Int J Antimicrob Agents (2012) 0.96
Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients. Pharmacogenomics (2010) 0.95
Different anesthetic techniques associated with different incidences of chronic post-thoracotomy pain: low-dose remifentanil plus presurgical epidural analgesia is preferable to high-dose remifentanil with postsurgical epidural analgesia. J Cardiothorac Vasc Anesth (2009) 0.94
Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus. Clin Pharmacokinet (2009) 0.94
Peritonitis due to Lactococcus cremoris in an automated peritoneal dialysis patient. Nephrol Dial Transplant (2003) 0.94
A simultaneous d-optimal designed study for population pharmacokinetic analyses of mycophenolic Acid and tacrolimus early after renal transplantation. J Clin Pharmacol (2011) 0.93
Case-control study of drug monitoring of β-lactams in obese critically ill patients. Antimicrob Agents Chemother (2012) 0.93
An overview of monitoring and supplementation of omega 3 fatty acids in cystic fibrosis. Clin Biochem (2007) 0.93
Evaluation of tumor necrosis factor-alpha, interleukin-6 and C-reactive protein plasma levels as predictors of bacteremia in patients presenting signs of sepsis without shock. Clin Microbiol Infect (1997) 0.92
1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation. Pharmacogenet Genomics (2007) 0.92
Time of drug administration, CYP3A5 and ABCB1 genotypes, and analytical method influence tacrolimus pharmacokinetics: a population pharmacokinetic study. Ther Drug Monit (2009) 0.91
Amikacin monotherapy for sepsis caused by panresistant Pseudomonas aeruginosa. Antimicrob Agents Chemother (2010) 0.91
Rapid quantification of six β-lactams to optimize dosage regimens in severely septic patients. Talanta (2012) 0.91
Optimal meropenem concentrations to treat multidrug-resistant Pseudomonas aeruginosa septic shock. Antimicrob Agents Chemother (2012) 0.91
The role of epithelial P2Y2 and P2Y4 receptors in the regulation of intestinal chloride secretion. Br J Pharmacol (2005) 0.91
Iodine and iron status of pregnant women in Lubumbashi, Democratic Republic of Congo. Public Health Nutr (2013) 0.90
IL-12Rβ1 deficiency and disseminated Mycobacterium tilburgii disease. J Clin Immunol (2013) 0.90
Continuous infusion of vancomycin in septic patients receiving continuous renal replacement therapy. Int J Antimicrob Agents (2013) 0.90
CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation. Pharmacogenomics (2010) 0.90
Hyperhomocysteinemia and venous thromboembolism: a risk factor more prevalent in the elderly and in idiopathic cases. Thromb Res (2002) 0.90
Pharmacokinetics of a loading dose of amikacin in septic patients undergoing continuous renal replacement therapy. Int J Antimicrob Agents (2011) 0.89
Glycosomal ABC transporters of Trypanosoma brucei: characterisation of their expression, topology and substrate specificity. Int J Parasitol (2010) 0.89
The glomerular filtration rate estimated by new and old equations as a predictor of important outcomes in elderly patients. BMC Med (2014) 0.88
The future of hospital laboratories. Position statement from the Royal Belgian Society of Clinical Chemistry (RBSCC). Clin Chem Lab Med (2009) 0.88
Significance of serum immune markers in identification of global functional impairment in the oldest old: cross-sectional results from the BELFRAIL study. Age (Dordr) (2013) 0.87
Liquid chromatography-tandem mass spectrometry or automated immunoassays: what are the future trends in therapeutic drug monitoring? Clin Chem (2012) 0.87
The prevalence of cardiac dysfunction and the correlation with poor functioning among the very elderly. Int J Cardiol (2011) 0.87
Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines. Ther Drug Monit (2013) 0.87
Correlation of tacrolimus levels in peripheral blood mononuclear cells with histological staging of rejection after liver transplantation: preliminary results of a prospective study. Transpl Int (2011) 0.87
Barcelona Consensus on Biomarker-Based Immunosuppressive Drugs Management in Solid Organ Transplantation. Ther Drug Monit (2016) 0.86
Verocytotoxin-producing Escherichia coli O128ab:H2 bacteremia in a 27-year-old male with hemolytic-uremic syndrome. J Clin Microbiol (2013) 0.86
Immunomodulatory activity of vardenafil on induced lung inflammation in cystic fibrosis mice. J Cyst Fibros (2012) 0.86
Monitoring of urea and potassium by reverse iontophoresis in vitro. Pharm Res (2007) 0.85
Mechanics of the canine diaphragm in ascites: a CT study. J Appl Physiol (1985) (2007) 0.85
Performance of serum cystatin-C versus serum creatinine in subjects with type 1 diabetes. Diabetes Care (2003) 0.85
Dysregulated proinflammatory and fibrogenic phenotype of fibroblasts in cystic fibrosis. PLoS One (2013) 0.85
Automated serum protein electrophoresis by Capillarys. Clin Chem Lab Med (2003) 0.84
Empirical models for dosage optimization of four beta-lactams in critically ill septic patients based on therapeutic drug monitoring of amikacin. Clin Biochem (2009) 0.84
Azithromycin fails to reduce increased expression of neutrophil-related cytokines in primary-cultured epithelial cells from cystic fibrosis mice. J Cyst Fibros (2009) 0.84
A new regimen for continuous infusion of vancomycin during continuous renal replacement therapy. J Antimicrob Chemother (2013) 0.84
Airway delivery of low-dose miglustat normalizes nasal potential difference in F508del cystic fibrosis mice. Am J Respir Crit Care Med (2009) 0.84
The influence of genetic polymorphisms of cytochrome P450 3A5 and ABCB1 on starting dose- and weight-standardized tacrolimus trough concentrations after kidney transplantation in relation to renal function. Clin Chem Lab Med (2006) 0.84
Endoxifen levels and its association with CYP2D6 genotype and phenotype: evaluation of a southern Brazilian population under tamoxifen pharmacotherapy. Ther Drug Monit (2012) 0.84
Accurate pre-operative localization of pathological parathyroid glands using 11C-methionine PET/CT. Contrast Media Mol Imaging (2008) 0.83
Influence of donor-recipient CYP3A4/5 genotypes, age and fluconazole on tacrolimus pharmacokinetics in pediatric liver transplantation: a population approach. Pharmacogenomics (2014) 0.83
Biotransformation enzymes and drug transporters pharmacogenetics in relation to immunosuppressive drugs: impact on pharmacokinetics and clinical outcome. Transplantation (2008) 0.83
Mechanism of the lung-deflating action of the canine diaphragm at extreme lung inflation. J Appl Physiol (1985) (2012) 0.83